×
About 1,435 results

ALLMedicine™ Blepharitis Center

Research & Reviews  366 results

Blepharitis Organism-Specific Therapy
http://emedicine.medscape.com/article/2014952-overview

Jan 23rd, 2023 - Specific Organisms and Therapeutic Regimens Blepharitis is a common chronic inflammation of the eyelid margin found in all ethnicities, genders, and age groups, though more common in those over the age of 50. [1] Clinically, there is irritation of...

Blepharitis Organism-Specific Therapy
https://emedicine.medscape.com/article/2014952-print

Jan 23rd, 2023 - Blepharitis is a common chronic inflammation of the eyelid margin found in all ethnicities, genders, and age groups, though more common in those over the age of 50.[1] Clinically, there is irritation of the eyelid margins as well as flaking/crusti...

Blepharitis Organism-Specific Therapy
https://emedicine.medscape.com/article/2014952-overview

Jan 23rd, 2023 - Specific Organisms and Therapeutic Regimens Blepharitis is a common chronic inflammation of the eyelid margin found in all ethnicities, genders, and age groups, though more common in those over the age of 50. [1] Clinically, there is irritation of...

Dyskeratosis Congenita and Related Telomere Biology Disorders - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/dkc/

Jan 19th, 2023 - Dyskeratosis congenita and related telomere biology disorders (DC/TBD) are caused by impaired telomere maintenance resulting in short or very short telomeres. The phenotypic spectrum of telomere biology disorders is broad and includes individuals ...

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
https://clinicaltrials.gov/ct2/show/NCT03926026

Jan 19th, 2023 - This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2 study evaluating the safety and tolerability of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD and BID for the treatment of acute exacerbat...

see more →

Guidelines  1 results

Blepharitis Preferred Practice Pattern®.
https://doi.org/10.1016/j.ophtha.2018.10.019
Ophthalmology Amescua G, Akpek EK et. al.

Oct 28th, 2018 - Blepharitis Preferred Practice Pattern®.|2018|Amescua G,Akpek EK,Farid M,Garcia-Ferrer FJ,Lin A,|organization & administration,therapeutic use,diagnosis,drug therapy,diagnosis,therapeutic use,pathology,organization & administration,standards,stand...

see more →

Drugs  90 results see all →

Clinicaltrials.gov  64 results

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
https://clinicaltrials.gov/ct2/show/NCT03926026

Jan 19th, 2023 - This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2 study evaluating the safety and tolerability of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD and BID for the treatment of acute exacerbat...

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
https://clinicaltrials.gov/ct2/show/NCT04675242

Dec 14th, 2022 - This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of ble...

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
https://clinicaltrials.gov/ct2/show/NCT04784091

Dec 2nd, 2022 - This Phase 3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of TP-03 to vehicle control for the treatment of Demodex blepharitis. The primary objective of the study is to assess the...

Phase III Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
https://clinicaltrials.gov/ct2/show/NCT05629390

Nov 29th, 2022 - The main study is designed to demonstrate the superiority of 0.25%TP-03 to vehicle for the treatment of Demodex blepharitis in China. The vehicle of TP-03 was selected as the control since there are no approved pharmaceutical treatments for Demode...

0.01% Hypochlorous Acid in the Treatment of Blepharitis
https://clinicaltrials.gov/ct2/show/NCT05608980

Nov 8th, 2022 - This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

see more →

News  39 results

Dupilumab as a Therapeutic Approach in Alopecia Universalis
https://www.mdedge.com/dermatology/article/259630/hair-nails/dupilumab-therapeutic-approach-alopecia-universalis
Michael J. Visconti, DO, Adam Richardson, DO et. al.

Nov 21st, 2022 - To the Editor: Atopic diseases, specifically atopic dermatitis (AD) and alopecia areata (AA), are at the forefront of a new era in dermatology involving molecular-directed therapy. Dupilumab is one specific example, having received US Food and Dru.

Red swollen eyelids
https://www.mdedge.com/atopic-dermatitis-challenge-center/article/259563/atopic-dermatitis/red-swollen-eyelids

Nov 18th, 2022 - This patient's symptoms are consistent with a diagnosis of blepharitis. Blepharitis is an inflammatory disorder of the eyelids that is frequently associated with bacterial colonization of the eyelid.

CDC Reports Five Cases of Ocular Monkeypox
https://www.medscape.com/viewarticle/982594

Oct 17th, 2022 - Although ocular monkeypox is rare, it can be a condition that threatens a person's sight, a Centers for Disease Control and Prevention (CDC) report says. The report details five people with monkeypox who developed eye complications from July throu...

Ocular Toxicity With Belantamab Mafodotin Is Not Influenced by Baseline Ocular Conditions in R/R Myeloma
https://www.onclive.com/view/ocular-toxicity-with-belantamab-mafodotin-is-not-influenced-by-baseline-ocular-conditions-in-r-r-myeloma

Aug 27th, 2022 - Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects (TEAEs) that may arise with belantamab mafodotin-blmf (Blenrep) in patients with relapsed/refractory multiple myeloma, according to a pos...

Prevalence and risk factors for ocular surface disease in patients with atopic dermatitis
https://www.mdedge.com/dermatology/article/250216/atopic-dermatitis/prevalence-and-risk-factors-ocular-surface-disease

Dec 25th, 2021 - Key clinical point: Ocular surface diseases (OSD), particularly conjunctivitis, are prevalent among patients with atopic dermatitis (AD), with the prevalence increasing with AD severity and childhood onset of AD. Major finding: Of all OSDs, lifeti.

see more →

Patient Education  14 results see all →